Written question asked by Jim Shannon (Democratic Unionist Party) on Tuesday, 16 December 2025, in the House of Commons. It was due for an answer on Thursday, 18 December 2025. It was answered by Ashley Dalton (Labour) on Wednesday, 14 January 2026 on behalf of the Department of Health and Social Care.
Prostate Cancer: Screening
- Question
-
To ask the Secretary of State for Health and Social Care, what assessment he has been made of the adequacy of national production capacity for PSMA radiotracers in the context of projected clinical demand for prostate cancer diagnosis.
- Answer
-
Prostate-specific membrane antigen (PSMA) radiotracers are commissioned for use as part of PET-CT prostate cancer imaging, as set out in the published clinical commissioning policy. Access to PET-CT, as with any healthcare service, is closely monitored.
Secondary information
- Type
- Written question
- Reference
- 100314
- Session
- 2024-26
- Subjects
- Diagnosis Production Prostate cancer Screening
- Link
- View this Written question on www.parliament.uk
Librarians' tools
- Timestamp
- 2026-01-14 15:36:50 +0000
- URI
- http://data.parliament.uk/writtenparliamentaryquestion/commons/2024-26/100314
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/writtenparliamentaryquestion/commons/2024-26/100314
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/writtenparliamentaryquestion/commons/2024-26/100314